EYES
Get informed when a big investor buys or sells
+ FollowOvervalued by 73.6% based on the discounted cash flow analysis.
| Market cap | $3.44 Million |
|---|---|
| Enterprise Value | $1.40 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $- |
| Beta | 5.03 |
| Outstanding Shares | - |
| P/E Ratio | -69.78 |
|---|---|
| PEG | 644.02 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.05 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 12.77 |
| Debt to Equity | 0.94 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulatio...